Publikation

Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice

Wissenschaftlicher Artikel/Review - 10.12.2012

Bereiche
PubMed
DOI

Zitation
Frebel H, Ludewig B, Kurrer M, Loffing-Cueni D, Wagner C, Vogel J, Richter K, Braunschweiler T, Schuepbach R, Nindl V, Oxenius A. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med 2012; 209:2485-99.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
J Exp Med 2012; 209
Veröffentlichungsdatum
10.12.2012
eISSN (Online)
1540-9538
Seiten
2485-99
Kurzbeschreibung/Zielsetzung

The inhibitory programmed death 1 (PD-1)-programmed death ligand 1 (PD-L1) pathway contributes to the functional down-regulation of T cell responses during persistent systemic and local virus infections. The blockade of PD-1-PD-L1-mediated inhibition is considered as a therapeutic approach to reinvigorate antiviral T cell responses. Yet previous studies reported that PD-L1-deficient mice develop fatal pathology during early systemic lymphocytic choriomeningitis virus (LCMV) infection, suggesting a host protective role of T cell down-regulation. As the exact mechanisms of pathology development remained unclear, we set out to delineate in detail the underlying pathogenesis. Mice deficient in PD-1-PD-L1 signaling or lacking PD-1 signaling in CD8 T cells succumbed to fatal CD8 T cell-mediated immunopathology early after systemic LCMV infection. In the absence of regulation via PD-1, CD8 T cells killed infected vascular endothelial cells via perforin-mediated cytolysis, thereby severely compromising vascular integrity. This resulted in systemic vascular leakage and a consequential collapse of the circulatory system. Our results indicate that the PD-1-PD-L1 pathway protects the vascular system from severe CD8 T cell-mediated damage during early systemic LCMV infection, highlighting a pivotal physiological role of T cell down-regulation and suggesting the potential development of immunopathological side effects when interfering with the PD-1-PD-L1 pathway during systemic virus infections.